Clinical trial · Interventional
Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices
NCT05124405CI-TRIAL-00112155active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To test the use of a continuous activity and heart rate tracker (Fitbit) and continuous glucose monitor (CGM) in monitoring daily exercise-related activities.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Diabetes | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Continuous Glucose Monitor | Other | — | UNRESOLVED |
| Fitbit | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Heart Rate Tracker (Fitbit)
- description
- continuous heart rate activity
- interventionNames
- Other: Fitbit
- Other: Continuous Glucose Monitor
- type
- EXPERIMENTAL
- label
- Continuous Glucose Monitor (CGM)
- description
- monitoring daily exercise-related activities
- interventionNames
- Other: Fitbit
- Other: Continuous Glucose Monitor
Primary outcomes (1)
- measure
- To evaluate the feasibility of the ( PA) Physical Activity intervention.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Men and women at least 18 years old * Body mass index (BMI) 25 kg/m2 * Engage in less than 150 minutes of moderate-intensity PA per week in the past month * Capable of participating in moderate-vigorous unsupervised exercise (as determined by the Physical Activity Readiness Questionnaire (PARQ) or a medical release from their physician) * Self-reported ability to walk one block without pain or discomfort * Have a smart phone with daily internet access that is compatible with the LibreLink app * Ability to speak, read, and write in English * For the cancer survivor cohort (participant accession number #21 and beyond), individuals must have been diagnosed with stage I-III breast or colorectal cancer and completed adjuvant therapy (i.e., chemo and/or radiation therapy). Exclusion Criteria: * Self-reported current diagnosis or history of type 1 diabetes or type 2 diabetes * Self-reported use of oral antidiabetic agents (OADs) * Previous or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness including gestational is allowed at the discretion for the investigator) * Current use of a continuous glucose monitor * Fasting glucose \> 125 mg/dL * Pregnancy * Self-reported health issues that limit physical activity * On dialysis * Work overnight shifts * Unwilling to use CGM * Current participation in other wellness or weight loss-related program or intervention * Currently on a low-carb diet * Unable to receive REDCap survey through their mobile phones
References
Publications (1)
- DERIVEDLiao Y, Brannon GE, Rethorst CD, Baum M, Bevers TB, Schembre SM, Basen-Engquist KM. Using Continuous Glucose Monitoring as a Biological Feedback Strategy to Motivate Physical Activity in Cancer Survivors: A Mixed-Methods Pilot Study. Cancer Control. 2025 Jan-Dec;32:10732748251359406. doi: 10.1177/10732748251359406. Epub 2025 Jul 28. PMID 40719638